Polygala Extract-Based Solutions for Specialized Attention-Deficit Hyperactivity Disorder Treatments

Publication ID: 24-11857592_0004_PTD

Published: October 28, 2025

Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Polygala Extract-Based Solutions for Specialized Attention-Deficit Hyperactivity Disorder Treatments,” Published Technical Disclosure No. 24-11857592_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857592_0004_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,592.

Summary of the Inventive Concept

The inventive concept adapts the original Polygala extract-based treatment for attention-deficit hyperactivity disorder (ADHD) to specific, niche markets and operational environments, enhancing its therapeutic value and applicability.

Background and Problem Solved

The original patent disclosed a method for treating ADHD using a composition comprising Radix Polygalae extract. However, it did not address the unique needs of individuals in high-altitude environments, high-stress occupations, or those with a history of traumatic brain injury, genetic predisposition, or co-occurring anxiety disorders. This inventive concept addresses these limitations by developing specialized variations of the original treatment.

Detailed Description of the Inventive Concept

The new inventive concept comprises five specialized solutions: 1) a system for treating ADHD in high-altitude environments, combining Radix Polygalae extract with an oxygen supplement; 2) a method for treating ADHD in subjects with high-stress occupations, incorporating a cortisol-reducing agent; 3) a system for treating ADHD in individuals with a history of traumatic brain injury, featuring a neuroprotective agent; 4) a method for treating ADHD in individuals with a genetic predisposition, utilizing a genetic modifier; and 5) a system for treating ADHD in subjects with co-occurring anxiety disorders, including an anxiolytic agent. These solutions are orally administered and tailored to address the specific challenges of each niche market or operational environment.

Novelty and Inventive Step

The new claims introduce novel combinations of the original Polygala extract-based treatment with additional agents and components, specifically designed to address the unique needs of specialized markets and operational environments. These combinations are non-obvious and provide a significant therapeutic advantage over the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include varying the ratio of Radix Polygalae extract to additional agents, using different formulations or delivery methods, or incorporating other synergistic compounds to enhance therapeutic efficacy. Variations could also involve adapting the solutions for use in other niche markets or operational environments, such as disaster relief or extreme weather conditions.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of ADHD treatment, specialized medicine, and niche market solutions. The targeted markets include high-altitude environments, high-stress occupations, traumatic brain injury, genetic predisposition, and co-occurring anxiety disorders, offering a substantial opportunity for market growth and expansion.

CPC Classifications

Section	Class	Group
A	A61	A61K36/69
A	A61	A61K9/0053
A	A61	A61K9/485
A	A61	A61K9/4825
A	A61	A61K9/4858
A	A61	A61K47/02
A	A61	A61K47/12
A	A61	A61P25/28
A	A61	A61K2236/333

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical compositions for neurological disorders, specifically ADHD treatments, involving botanical extracts and targeted therapeutic interventions

Person of Ordinary Skill (PHOSITA) Profile

A pharmacologist or pharmaceutical researcher with expertise in herbal medicine, neurological treatment formulations, and drug delivery systems, holding advanced degrees in pharmaceutical sciences or related fields

Obviousness Rationale

A PHOSITA would recognize that the PTD's specialized ADHD treatment variations represent predictable extensions of the source patent's core Polygala extract methodology by systematically addressing specific patient subpopulations and environmental contexts using known pharmaceutical combination strategies.

Obvious Combinations & Variations

Source Patent Element

Oral administration of Radix Polygalae extract for ADHD treatment

PTD Variation

Adding oxygen supplement for high-altitude ADHD treatment

Obviousness Reasoning

Combining supplemental oxygen with existing ADHD treatment is a predictable solution for addressing physiological challenges in altitude-related cognitive performance, utilizing standard pharmaceutical combination techniques

Source Patent Element

Botanical extract composition for managing ADHD symptoms

PTD Variation

Incorporating cortisol-reducing agent for high-stress occupation contexts

Obviousness Reasoning

Modifying ADHD treatment with stress-management compounds represents a known approach for addressing comorbid stress-related cognitive impairments, following established pharmaceutical intervention strategies

Source Patent Element

Method of treating ADHD symptoms through botanical extract

PTD Variation

Adding neuroprotective agent for traumatic brain injury patients

Obviousness Reasoning

Extending treatment protocols to specific neurological subpopulations by incorporating protective compounds is a standard pharmaceutical design approach with predictable therapeutic enhancement potential

Source Patent Element

Oral administration of ADHD treatment composition

PTD Variation

Including genetic modifier for genetically predisposed individuals

Obviousness Reasoning

Tailoring pharmaceutical interventions to genetic profiles represents a conventional personalized medicine strategy with well-understood methodological precedents

Source Patent Element

Botanical extract for managing ADHD symptoms

PTD Variation

Integrating anxiolytic agent for patients with co-occurring anxiety disorders

Obviousness Reasoning

Addressing comorbid conditions through targeted pharmaceutical combinations is a standard clinical approach with predictable therapeutic optimization potential

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this publication would be considered obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable pharmaceutical extensions of US Patent 11857592's core Polygala extract ADHD treatment methodology, utilizing standard combination strategies and addressing specific patient subpopulation needs through conventional medical intervention techniques.

Original Patent Information

Patent Number	US 11,857,592
Title	Polygala extract for the treatment of attention-deficit hyperactivity disorder
Assignee(s)	BioLite Inc.